# Program at a Glance

| Date | Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|---|
| July 10th | 18:00-18:10 | Welcome Address | | | |
| | 18:10-19:30 | Keynote Lectures | Alice T. Shaw<br>Hiroyuki Mano | Hiroyuki Mano<br>(National Cancer Center Research Institute) | Construction of Cancer Genomic Medicine Platform in Japan |
| | | | | Alice T. Shaw<br>(Massachusetts General Hospital, Harvard Medical School) | Evolution of Resistance and Tumor Heterogeneity in ALK-Positive Lung Cancer |
| | 19:50-21:50 | Welcome Party | | | |
| July 11th | 8:30-10:00 | 1. Personalized treatment strategies in lung cancer | Alexander Drilon<br>Koichi Goto | Shinji Kohsaka<br>(National Cancer Center Research Institute) | Application of a High-throughput Functional Evaluation of Variants of Unknown Significance to Personalized Medicine |
| | | | | Alexander Drilon<br>(Memorial Sloan Kettering Cancer Center) | Advances in Targeted Therapy For Driver-Positive Subsets Of Non-Small Cell Lung Cancers |
| | | | | Koichi Goto<br>(National Cancer Center Hospital East) | Development of a Nationwide Genomic Screening Project (LC-SCRUM-Japan) for the Establishment of Precision Medicine in Lung Cancer |
| | 10:00-10:20 | Break | | | |
| | 10:20-11:50 | 2. Latest advances in small cell lung cancer and mesothelioma | Charles M. Rudin<br>Hiroyuki Aburatani | Charles M. Rudin<br>(Memorial Sloan Kettering Cancer Center) | Latest Advances in Small Cell Lung Cancer |
| | | | | Hiroyuki Aburatani<br>(The University of Tokyo) | Comprehensive Molecular Analysis of Malignant Pleural Mesothelioma |
| | | | | Shoutaro Tsuji<br>(Kanagawa Cancer Center Research Institute) | Development of Precise Diagnosis with a New Mesothelioma Marker, Sialylated HEG1 |
| | 11:50-12:50 | Lunch and Poster View | | | |
| | 12:50-14:20 | Poster Presentation | | | |
| | 14:20-15:50 | 3. Targeting KRAS-mutant lung cancer | Ferdinandos Skoulidis<br>Hiroki Nagase | Ferdinandos Skoulidis<br>(The University of Texas MD Anderson Cancer Center) | Dissecting Immunotherapy Responses in Subgroups of *KRAS*-Mutant Lung Adenocarcinoma |
| | | | | Hiromichi Ebi<br>(Aichi Cancer Center Research Institute) | Combination Therapies Targeting KRAS Mutant Lung Cancer |
| | | | | Hiroki Nagase<br>(Chiba Cancer Center Research Institute, Chiba University) | Targeting the RAS Gene against Cancer |
| | 15:50-16:10 | Break | | | |
| | 16:10-17:40 | 4. Overcoming resistance to targeted therapies in lung cancer | Christine Lovly<br>Takashi Takahashi | Takashi Takahashi<br>(Nagoya University) | ROR1: An Achilles Heel of Lung Cancer |
| | | | | Christine Lovly<br>(Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center) | Overcoming Resistance to Mutant-Selective EGFR Inhibition in EGFR-mutant Lung Cancer |
| | | | | Ryohei Katayama<br>(Cancer Chemotherapy Center, JFCR) | Drug Repurposing: Overcoming the Acquired Resistance with Other Target Inhibitors |
| | 18:00-19:00 | Meet-the Expert Evening (all participants) | | | |
| | 19:30-21:30 | Banquet | | | |

| Date | Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|---|
| July 12th | 8:30-10:00 | 5. Novel immunotherapy strategies: Beyond PD-1/PD-L1 | Justin F. Gainor<br>Hiroyoshi Nishikawa | Hiroyoshi Nishikawa<br>(Research Institute/EPOC, National Cancer Center, Nagoya University) | Complexed Immune Suppressive Mechanisms In Tumor Microenvironment |
| | | | | Justin F. Gainor<br>(Massachusetts General Hospital) | Emerging Immunotherapy Combinations in the Management of Non-Small Cell Lung Cancer |
| | | | | Koji Tamada<br>(Yamaguchi University) | Revolution of CAR-T Cell Technology to Develop Next-generation Cancer Immunotherapy |
| | 10:00-10:20 | Break | | | |
| | 10:20-11:50 | 6. Primary and acquired mechanisms of resistance to immunotherapies | Roy S. Herbst<br>Heiichiro Udono | Kenji Chamoto<br>(Kyoto University) | The Role of Fatty Acid Oxidation of T Cells in the Synergistic Effect With PD-1 Blockade |
| | | | | Heiichiro Udono<br>(Okayama University) | Anti-diabetes Drug, Metformin, Drives Metabolic Reprogramming of Tumor Microenvironment, Leading to Inhibition of Tumor Growth |
| | | | | Roy S. Herbst<br>(Yale Cancer Center/Yale School of Medicine/Smilow Cancer Hospital) | Primary and Acquired Mechanisms of Resistance to Immunotherapies |
| | 11:50-12:50 | Lunch | | | |
| | 12:50-14:20 | 7. Tumor heterogeneity and circulating tumor DNA | Maximilian Diehn<br>Seiji Yano | Seiji Yano<br>(Cancer Research Institute, Nano Life Science Institute, Kanazawa University) | Inter-organ Heterogeneity on Mechanisms of Targeted Drug Resistance -Central Nervous System (CNS) vs extra CNS- |
| | | | | Maximilian Diehn<br>(Stanford University School of Medicine) | Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring |
| | | | | Tsukasa Kadota<br>(National Cancer Center Research Institute, The Jikei University School of Medicine) | Circulating MicroRNAs as Biomarkers for Early Detection and Prediction of Immunotherapeutic Response in Lung Cancer Patients |
| | 14:20-14:40 | Break | | | |
| | 14:40-16:10 | 8. Tumor microenvironment and implications for treatment | Miguel F. Sanmamed<br>Kohei Miyazono | Atsushi Enomoto<br>(Nagoya University) | Heterogeneity of Cancer-Associated Fibroblasts and its Significance in Tumor Progression and Response to Therapies |
| | | | | Miguel F. Sanmamed<br>(Yale School of Medicine) | Modeling Patient-derived Lung Tumor Microenvironment To Develop Immunotherapies |
| | | | | Kohei Miyazono<br>(The University of Tokyo) | Regulation of the Development of Lung Cancer by TGF-β Signaling |
| | 16:10-16:20 | Closing Remarks | | | |